



Year: 2018

HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic

von Braun, Amrei ; Sekaggya-Wiltshire, Christine ; Bachmann, Nadine ; Ssemwanga, Deogratius ; Scherrer, Alexandra U ; Nanyonjo, Maria ; Kapaata, Anne ; Kaleebu, Pontiano ; Günthard, Huldrych F ; Castelnovo, Barbara ; Fehr, Jan ; Kambugu, Andrew

Abstract: **BACKGROUND** Little is known about prevalence of drug resistance among HIV-infected Ugandans, a setting with over 15 years of public-sector access to antiretroviral therapy (ART) and where virological monitoring was only recently introduced. **SETTING** This study was conducted in the adults' out-patient clinic of the Infectious Diseases Institute, Kampala, Uganda. **METHODS** HIV genotyping was performed in ART naïve patients and in treatment experienced patients on ART for six months with virological failure (1000 copies/mL). **RESULTS** A total of 152 ART naïve and 2511 ART experienced patients were included. Transmitted drug resistance was detected in 9 (5.9%) patients. After a median time on ART of 4.7 years (interquartile range (IQR): 2.5-8.7), 190 patients (7.6%) had virological failure with a median viral load of 4.4 log₁₀ copies/mL (IQR:3.9-4.9). Additionally, 146 patients had a viral load between 51 and 999 copies/ml. Most patients with virological failure (142, 74.7%) were on first-line ART. For 163 (85.8%) ART experienced patients genotype results were available. Relevant drug resistance mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to two drug classes, and 11 (6.7%) had resistance to all drug classes available in Uganda. **CONCLUSION** The prevalence of transmitted drug resistance was lower than recently reported by the WHO. With 92% of all patients virologically suppressed on ART, the prevalence of virological failure was low when a cut-off of 1000 copies/mL is applied, and is in-line with the third of the 90-90-90 UNAIDS targets. However, most failing patients had developed multi-class drug resistance. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

DOI: <https://doi.org/10.1097/QAI.0000000000001717>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-151827>

Journal Article

Accepted Version

Originally published at:

von Braun, Amrei; Sekaggya-Wiltshire, Christine; Bachmann, Nadine; Ssemwanga, Deogratius; Scherrer, Alexandra U; Nanyonjo, Maria; Kapaata, Anne; Kaleebu, Pontiano; Günthard, Huldrych F; Castelnovo, Barbara; Fehr, Jan; Kambugu, Andrew (2018). HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic. *Journal of Acquired Immune Deficiency Syndromes*, 78(5):566-573.

DOI: <https://doi.org/10.1097/QAI.0000000000001717>

HIV-1 drug resistance among Ugandan adults attending an urban out-patient clinic

Authors:

Amrei von Braun^{*1,2}, Christine Sekaggya-Wiltshire^{*1}, Nadine Bachmann^{2,3}, Deogratius Ssemwanga⁴, Alexandra U. Scherrer^{2,3}, Maria Nanyonjo⁴, Anne Kapaata⁴, Pontiano Kaleebu⁴, Huldrych F. Günthard^{2,3}, Barbara Castelnuevo¹, Jan Fehr^{**2}, Andrew Kambugu^{**1}

Affiliations:

¹Infectious Diseases Institute, College of Health Sciences, Makerere University, P.O. Box 22418, Kampala, Uganda

²Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland

³Institute of Medical Virology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland

⁴Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) and London School of Hygiene and Tropical Medicine, Uganda Research Unit, P.O. Box 49, Entebbe Uganda

⁵Department of Public Health at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

*Corresponding Author: Amrei von Braun, Division of Infectious Diseases and Tropical Medicine, Leipzig University Hospital, Liebigstrasse 20, 04103 Leipzig, Germany, Email: amrei.braun@medizin.uni-leipzig.de, Phone: 0049 151 20242838, Fax: 0049 341 9724979

Current address: Amrei von Braun, Division of Infectious Diseases and Tropical Medicine, Leipzig University Hospital, Liebigstrasse 20, 04103 Leipzig, Germany, Email: amrei.braun@medizin.uni-leipzig.de, Phone: 0049 151 20242838, Fax: 0049 341 9724979

** Authors contributed to the manuscript equally

The authors report no conflicts of interest related to this work.

Meetings: Part of this work was presented at the following conference: HIV Drug Therapy Glasgow, Glasgow, Scotland, October 24 - 26, 2016

Sources of Support: Swiss HIV Cohort Study, Gilead Sciences

Running Title: HIV drug resistance among Ugandan adults

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

Abstract

Background: Little is known about prevalence of drug resistance among HIV-infected Ugandans, a setting with over 15 years of public-sector access to antiretroviral therapy (ART) and where virological monitoring was only recently introduced.

Setting: This study was conducted in the adults' out-patient clinic of the Infectious Diseases Institute, Kampala, Uganda.

Methods: HIV genotyping was performed in ART naïve patients and in treatment experienced patients on ART for \geq six months with virological failure (≥ 1000 copies/mL).

Results: A total of 152 ART naïve and 2511 ART experienced patients were included. Transmitted drug resistance was detected in 9 (5.9%) patients. After a median time on ART of 4.7 years (interquartile range (IQR): 2.5-8.7), 190 patients (7.6%) had virological failure with a median viral load of 4.4 log₁₀ copies/mL (IQR:3.9-4.9). Additionally, 146 patients had a viral load between 51 and 999 copies/ml. Most patients with virological failure (142, 74.7%) were on first-line ART. For 163 (85.8%) ART experienced patients genotype results were available. Relevant drug resistance mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to two drug classes, and 11 (6.7%) had resistance to all drug classes available in Uganda.

Conclusion: The prevalence of transmitted drug resistance was lower than recently reported by the WHO. With 92% of all patients virologically suppressed on ART, the prevalence of virological failure was low when a cut-off of 1000 copies/mL is applied, and is in-line with the third of the 90-90-90 UNAIDS targets. However, most failing patients had developed multi-class drug resistance.

Keywords: HIV drug resistance; virological failure; Uganda; treatment monitoring

INTRODUCTION

In Uganda, antiretroviral therapy (ART) was first made available for selected HIV-infected patients through the private sector and small pilot research studies in 1998, approximately 5 years earlier than in other countries in sub-Saharan Africa.¹ When low-cost, high-quality generic antiretroviral drugs became available in 2001, the Ugandan government introduced ART for HIV-infected patients with advanced HIV disease funded by the World Bank Multi-Sectoral AIDS Project (MAP).^{2,3} Since 2003, ART in Uganda is largely funded by the U.S. President's Emergency Plan for HIV/AIDS Relief (PEPFAR) and has been made available to a large part of HIV-infected Ugandans based on existing national guidelines.⁴ According to the Ugandan Population HIV Impact Assessment (UPHIA), 1.3 Million people in Uganda were living with HIV in 2016 (prevalence 6.2% among adults), and the ART coverage was 60%.⁵ In-line with WHO guidelines, first-line treatment regimens in Uganda consist of a fixed-dose combination of two nucleoside-reverse-transcriptase-inhibitors (NRTI), either AZT/3TC or TDF/3TC, with one non-nucleoside-reverse-transcriptase-inhibitor (NNRTI), either nevirapine or efavirenz.⁴ Second-line treatment options are reserved for patients failing first-line treatment and consist of a protease inhibitor (PI) with two NRTI. Integrase Inhibitors such as raltegravir or dolutegravir are considered third-line drugs and were only available through research studies or private purchase at the time of study implementation. Previous studies on the prevalence of transmitted drug resistance in Uganda mainly focused on key populations or had small patient numbers. For instance, a study from 2004 included 81 patients from Kampala and found a prevalence of transmitted drug resistance of 7%.⁶ A more recent, but similarly small study examined transmitted drug resistance among Ugandan fishing communities, which is a high-risk group around Lake Victoria, and found resistance to NNRTI in three of 47 (6.4%) treatment naïve patients.⁷

As resistance mutations impact therapeutic outcomes, in developed countries genotypic resistance testing is recommended before starting treatment and before considering a switch of regimen.⁸ However, genotypic resistance testing remains costly and is therefore reserved for research or privately paid for in resource-limited countries including Uganda. A meta-analysis has shown a higher prevalence of HIV drug resistance among ART naïve patients in East Africa compared to other regions with a 29% increase of HIV drug resistance per year since the ART roll out, compared to lower rates in Southern Africa (14%) and Central and West Africa (3%).⁹ Due to growing evidence of increasing resistance to ART, there is need for further documentation of the current state of both acquired and transmitted drug resistance in Uganda.^{10–12} The objective of our study was to report the type and frequency of HIV drug resistance among ART naïve, as well as ART-experienced urban Ugandan adults by performing a cross-sectional study in one of the largest HIV treatment centers in Kampala.

METHODS

Setting

We conducted a cross-sectional study at the adult clinic of the Infectious Diseases Institute (IDI), College of Health Sciences, Makerere University in Kampala, Uganda, between June 4 and September 30, 2015. The IDI is a center of excellence for HIV treatment located at the national referral hospital complex, and currently cares for over 8000 registered patients infected with HIV.¹³ Up to December 2014, patients on ART were monitored with CD4 count measurements every 6 months, while viral load testing was made available only for patients who were thought to have treatment failure based on immunological or clinical criteria.¹⁴ All HIV-infected patients presenting at the IDI during the study period, who were 18 years or older, ART naïve or on ART for ≥ 6 months, and due for a CD4 cell count measurement were eligible for study participation. As defined by the WHO, transmitted HIV drug resistance is detected in ARV naïve people with no history of antiretroviral drug exposure.¹⁵ Therefore, all

patients currently without ART but prior exposure to ART, such as women with a history of treatment for the prevention-of-mother-to-child-transmission (PMTCT), were excluded. Patients with a history of any blinded ART regimen in the context of clinical trials were excluded as well. Patients were consecutively screened and enrolled by trained study staff.

Study procedures

For each participant, we collected information on demographics, social and educational background, ART history, concomitant medication including herbal remedies, alcohol and recreational drug-use, information on adherence by self-report, side effects, past CD4 cell counts and, if applicable, past viral load results. Results for viral loads and genotypic resistance testing were collected prospectively. Venous blood was drawn from patients on ART for viral load measurement, and plasma storage at -80°C. CD4 cell counts (BD FACSCalibur Flow Cytometer: 4-Color) and viral load measurements (COBAS® AmpliPrep / COBAS® TaqMan® HIV-1 Test, v2.0, Roche Diagnostics, cut-off 20 copies/ml) were performed at the Makerere-University-John-Hopkins-University (MUJHU) CORE laboratory certified by the College of American Pathologists. For ART naïve patients, blood was sampled for plasma storage only. Genotyping was requested at the MRC/UVRI Uganda Research Unit on AIDS, HIV Drug Resistance Reference Laboratory for all ART naïve patients and ART experienced patients with virological failure, defined as viral load ≥ 1000 copies/mL. As previously described, viral RNA was extracted from 140ul of plasma using the QIAmp Viral RNA mini kit (Qiagen), the entire protease (codons 1–99) and amino terminus of reverse transcriptase (codons 1–320) were amplified and sequenced using the ABI 3500 machine (Applied Biosystems).¹² Sequences were base-called using Sequencher v5.2.4 and drug resistance mutations (DRMs) were analysed using the Stanford HIVdb Program (<https://hivdb.stanford.edu/hivdb/by-mutations>). The assigned DRMs were interpreted using the 2009 WHO list for epidemiological surveys. HIV-1 subtyping was done using SCUEAL (http://www.datamonkey.org/dataupload_scueal.php) and REGA (www.bioafrica.net/rega-

genotype/html/subtypinghiv.html) online software. Basic phylogenies were performed to determine sequence relatedness and to rule out contaminations. Viral sequences are available in Genbank accession numbers MF565526 – MF565688.

Data management and statistical analysis

Data was collected from patient interview, extracted from the electronic medical record (*Integrated Clinic Enterprise Application, ICEA*)¹⁶ or paper file and entered into DataFax forms specially designed for this study. The data management system DataFax is designated to manage paper data forms. The forms are faxed to the DataFax server where they are read using intelligent characters-recognition and populate the study database.

Univariate and multivariate logistic regressions were done to identify risk factors for virological failure in patients on first- and second-line ART. The following potential risk factors or correlates for virological failure were considered in the univariate analysis: age, gender, current ART regimen, years on ART, CD4 cell count, number of children, marital status, adherence to ART, reported side effects, and previous viral load measurements. For the subsequent multivariate analysis we selected all variables with a p-value < 0.1 in the univariate model, checked for multicollinearity, and in case of multicollinearity selected according to clinical relevance.

Ethical considerations

This study was reviewed and approved by the Makerere University School of Biomedical Research and Ethics Committee (SBS254), and the Uganda National Council for Science and Technology (HS 1800). The study was registered on ClinicalTrials.gov (NCT02507921). Written informed consent was obtained from all participants prior to enrollment. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.

RESULTS

A total of 2808 participants were enrolled in the study consisting of 220 ART naïve and 2588 ART experienced respectively. Figure 1 depicts the disposition of patients from screening to enrollment.

ART naïve patients

After withdrawing 14 patients with a history of PMTCT, 206 ART naïve patients were included. The median age was 33 years (IQR: 26-41), and the majority of patients had WHO disease stage 1 (84, 40.8%) or 2 (76, 36.9%). The median CD4 cell count was 511 cells/uL (IQR: 284-713). A total of 91 (44.2%) were either married or cohabitating, of which 59 (64.8%) reported to have an HIV-infected partner. The majority of the partners (54, 91.5%) were already on ART. Fourteen patients (6.8%) reported to have HIV-infected children.

Drug resistance testing could be performed in 152 ART naïve patients. Mutations associated with HIV drug resistance were found in 9/152 (5.9%) patients. Five patients (5/152, 3.3%) had any NRTI mutation (K65R: 1, M184V: 2, other: 2), and 8/152 (5.3%) had any NNRTI mutation (K101E: 3, Y181C: 2, K103N: 2, other: 4). No major PI mutation was detected.

ART experienced patients

After withdrawing 77 patients, 2511 ART experienced patients were included in this study, of which 1577 (62.8%) were female. Patients were withdrawn for the following reasons: history of blinded ART regimen (n=59), current ART regimen <6 months (n=12), and unwillingness to give a blood sample (n=6). Overall, study participants had been on ART for a median time of 4.7 years (IQR: 2.5-8.7 years). A total of 190 (7.6%) participants had virological failure with a median viral load of 4.4 log₁₀ copies/mL (IQR: 3.9-4.9 log₁₀ copies/mL). The majority of patients with virological failure were female (131/190, 69.0%) and on first-line ART (142/190, 74.7%). Table 1 shows baseline characteristics of study participants with virological suppression, as well as virological failure disaggregated by subjects failing first- and second-line ART regimens.

Risk factors for virological failure in patients failing first- and second-line ART were evaluated by univariate and multivariate analyses. As shown in Figure 2 for all patients, virological failure was significantly more likely in patients on second-line ART (adjusted odds ratio (aOR): 2.95, 95% confidence interval (95%CI): 1.87-4.65). Furthermore, being separated from the spouse (aOR: 1.86, 95%CI: 1.12-3.01) and reported side effects (aOR: 1.94, 95%CI: 1.18-3.19) were associated with virological failure. Previous viral load measurements (aOR: 0.55, 95%CI: 0.37-0.83), as well as excellent adherence (aOR: 0.41, 95%CI: 0.24-0.71) were protective of virological failure. Results of the univariate and multivariate analysis were further disaggregated by patients failing on first- and second-line ART. For patients on first-line ART (Table 2A), reported side-effects (aOR: 2.01, 95%CI: 1.17-3.46), as well as living separated from the spouse (aOR: 2.21, 95%CI: 1.29-3.81) were strongly associated with virological failure. Excellent adherence was protective of virological failure (aOR: 0.33, 95%CI: 0.18-0.61). In our study population, virological failure was significantly more likely to occur in patients on second-line treatment. In these patients (Table 2B), virological failure was associated with being single or separated from the spouse (aOR: 1.46, 95%CI: 0.55-3.92). A low CD4 cell count was not associated with virological failure. However, this may be due to a small sample size of patients failing on second-line treatment (N=48). Previous viral load measurements (aOR: 0.21, 95%CI: 0.09-0.52) were strongly protective of virological failure in patients on second-line ART.

Of 190 patients with a viral load >1000 copies/mL, HIV genotyping tests were available from 163 (85.8%) cases. HIV subtypes A (47.2%) and D (34.4%) were most common, 16.0% were recombinants. Subtypes C (1.8%) and G (0.6%) were rarely seen. Relevant drug resistance mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to two drug classes, and 11 (6.7%) had resistance to all three drug classes available in Uganda. PI mutations were observed in 13 (8.0%) patients. Any NRTI mutation was found in 122 (74.8%) patients, most commonly M184V (65.0%). A total of 125 (76.7%) patients had any

NNRTI mutation, most commonly K103N (42.9%). Of the 163 patients with available resistance testing, 28 (17.2%) had a K65R mutation. Almost all of these patients were currently on treatment with tenofovir (22/28, 78.6%). Figures 3 A&B show the resistance mutations found in patients failing first- and second-line ART with available sequence data.

In this study, resistance testing was done only in patients with a viral load >1000 copies/mL. A viral load between 51 and 500 copies/mL was detected in 127 (5.1%) participants (median viral load 130 copies/mL, IQR: 82-201 copies/mL), while 19 (0.8%) study participants had a viral load between 501 and 999 copies/mL (median viral load 623 copies/mL, IQR: 565-797 copies/mL). Thus, if a cut-off of 50 copies/mL is applied, as is the case in resource-rich settings, the rate of virological failure almost doubles to 345 patients (13.4%).

DISCUSSION

Our study indicates a low level of transmitted HIV drug resistance in this large urban HIV treatment center in a setting with public-sector ART access for more than one and a half decades. Given the paucity of published HIV drug resistance studies in ART naïve individuals in the region, our findings provide some insight on the level of transmitted drug resistance for similar settings in the region. Additionally, our study found a high rate of virological suppression. With over 92% of all patients virologically suppressed on ART, the overall prevalence of virological failure was low in our study population, and this is in-line with the third of the 90-90-90 UNAIDS targets.¹⁷ However, most failing patients had developed multi-class drug resistance.

Transmitted drug resistance

While there is limited data available on acquired resistance in Uganda, there is even less on transmitted drug resistance among HIV-infected Ugandans.¹² We found a proportion of 5.9% among our study population, which according to the WHO grading system is the cut-off between low (<5%) and moderate (5-15%). Despite over 10 years of widespread ART

availability in Uganda, according to this finding the prevalence of transmitted drug resistance in adults seeking care in our clinic seems to be low. Furthermore, mutations to PI, which are commonly used as second-line treatment options, were not observed. These findings are in line with previous studies from Uganda, which showed low rates of transmitted drug resistance in rural areas, as well as in urban settings ten years after the introduction of ART.^{6,18}

The most recent report on HIV drug resistance published by the WHO found a high proportion of patients with pretreatment drug resistance in Uganda.¹⁵ According to the WHO definition, pretreatment drug resistance is detected in treatment naive people initiating ART or people with prior antiretroviral drug exposure initiating or reinitiating first-line ART. Thus, pretreatment drug resistance includes transmitted drug resistance but can be acquired as well. The data on pretreatment drug resistance from Uganda included 342 adults (203 women, 65.4%), of which 296 (78.7%) had no prior exposure to ART. According to the report, levels of NNRTI pretreatment drug resistance were greater than 10% in three out of four countries in the African region, ranging from 8.1% (95% CI 4.3–14.7) in Cameroon to 15.4% (95% CI 10.3–22.5) in Uganda. Any transmitted drug resistance mutation was found in 18.1% (95% CI 12.7–25.2) of Ugandan patients. Compared to the WHO report our findings on transmitted drug resistance are much lower. Generally, surveillance data can be heterogeneous. The WHO report used a nationally representative sampling method described in detail in the report as opposed to site specific data. Secondly, considerable fluctuations over time have been observed in other countries, which can so far only partly be explained. One reason for these fluctuations was the introduction of new drugs as seen for boosted PIs in Switzerland.¹⁹ We conclude that more data is needed in order to complete the picture.

Virological failure

Our study found a high rate of virological suppression. Using a cut-off for virological failure of 1000 copies/mL, over 92% of all patients were suppressed on ART, which is in-line with

the third of the 90-90-90 UNAIDS targets.¹⁷ This is especially encouraging because for several years these patients were monitored using CD4 cell measurements only. Optimal adherence, high-quality clinical management, and consistent drug supplies probably contributed to these outcomes. The high proportion of patients virologically suppressed on first-line treatment is in line with findings from other studies previously conducted at the IDI.²⁰ In order to maintain a high rate of virological suppression the clinic adopted several differentiated care models, such as the nurse-visit or pharmacy-refill program.²¹ In both models, task shifting enables clinicians to concentrate on challenging cases. As the IDI is a center of excellence for HIV care, our study findings cannot be generalized. This aspect becomes even more apparent if our results are compared to the data provided by the UPHIA, which reports a prevalence of virological suppression among all HIV-positive Ugandan adults aged 15 to 64 of only 59.6% (62.9% among females and 53.6% among males).⁵ However, the results of our study demonstrate how well patients can do within an optimal setting. Nevertheless, it is notable that the proportion of patients with virological failure doubles if a cut-off of 50 copies/mL is applied, as is standard in many resource-rich settings. In our study, 146 patients had a viral load between 51 and 999 copies/mL. Using a cut-off of 1000 copies/mL for treatment failure makes sense in the context of “treatment as prevention”, as it is well described that transmission practically does not take place below this cut-off. However, the development of HIV drug resistance among patients with low-level viremia may be underestimated. In fact, a recent nation-wide study from France found that 48.5% of samples from patients with a viral load between 51 and 200 copies/mL harbored resistance mutations.²² Furthermore, recently published data from a South African cohort study which included over 70 000 HIV-positive patients from 57 clinical sites identified low-level viraemia (defined as a viral load of 51-999 copies/mL) in 23% of patients on first-line treatment. According to the authors, low-level viraemia was associated with increased hazards of virological failure (hazard ratio [HR] 2.6, 95% CI 2.5–2.8; $p < 0.0001$) and switch to

second-line ART (HR 5.2, 4.4–6.1; $p < 0.0001$) compared with virological suppression of less than 50 copies/mL.²³ These findings challenge the definition of therapeutic failure in guidelines using a cut-off of 1000 copies/mL, and evidence suggests that strategies for the management of low-level viraemia need to be incorporated into international guidelines in order to meet UNAIDS-defined targets.

Acquired drug resistance

The high proportion of virological suppression on ART is encouraging. However, most study participants with virological failure had developed resistance to more than one drug class, suggesting that failing regimens not identified by CD4 cell count monitoring in a timely fashion had been in place for a prolonged period. This study finding is most worrisome as efficacious treatment options are limited for patients with multi-class drug resistance in this setting, which puts these patients at high risk of disease progression and transmission of resistant virus strains. The accumulation of drug resistance mutations over time in patients with continued virological failure was shown in previously conducted studies from Uganda and other sub-Saharan African countries.^{24,25} A systematic review and meta-analysis which included 8376 patients from 8 cohorts and two prospective studies showed a significantly higher proportion of resistance mutations at virological failure in patients monitored less frequently.²⁶ This is in-line with our observation that previous viral load measurements were protective of virological failure and thus the development of resistance mutations in patients on second-line ART.

The distribution of mutations found in our study is largely in line with findings from other studies conducted in the region. A systematic review of 89 studies with 13288 patients from sub-Saharan Africa found the prevalence of viral suppression at 12 months to be 76%.²⁷ In patients with virological failure the most common resistance mutations reported by the authors were M184V (65%) and K103N (52%) while thymidine-analogue mutations (TAMs) and K65R were much less common (5 - 20%). The PharmAccess African Studies to Evaluate

Resistance (PASER), which evaluated data from six African countries, found that 8.5% of patients with virological failure after 11-15 months of ART have more than one TAM.²⁸

Among the 163 patients with available resistance data in our study, 54 (33.1%) were on TDF-containing regimens. Of these, 22 (40.7%) had a K65R mutation compared to only 28 (17.8%) among the entire study population. A recent study on the global epidemiology of HIV drug resistance after failure of WHO recommended first-line regimens was recently published.²⁹ In low- and middle-income countries, the authors found drug resistance in a high proportion of patients failing treatment with tenofovir-containing regimens. Tenofovir resistance was highest in sub-Saharan Africa (370/654, 57%). The study findings reported here, as well as observations from other studies on emergence of resistance in the region stress the need for enhanced surveillance and preventive measures.^{30,31}

Our study has a few limitations. For one, women currently without ART but with a history of PMTCT (WHO option B) were excluded from participation. These women were excluded because they did not fulfill the criteria of being ART naïve or on a stable regimen for at least 6 months. However, HIV drug resistance today plays an important role in these women, and further research focused specifically on this group is needed. A further limitation is that we failed to collect information on pregnancy, as well as on tuberculosis co-infection. Both aspects are relevant in the context of treatment failure and should have been taken into account. Furthermore, a number of resistance tests failed. We were unable to ascertain the cause of failure to genotype 54 samples of ART naïve and 36 samples of ART experienced participants. While this did not result in a selection bias, it reduced the number of available tests for this study analysis. However, the number of failed test seems to be in-line with other studies.²²

We conclude that the UNAIDS goal of 90% virological suppression on ART is achievable within an optimal treatment setting. However, if treatment failure occurred, a high proportion had developed multi-class drug resistance, which massively complicates sufficient treatment

in this setting. Furthermore, if a cut-off for treatment failure of 50 copies/mL is applied the rate of patients with virological failure doubles and most likely resistance among these patients is underestimated. As ART scale-up continues in the region, close surveillance of HIV drug resistance - both acquired and transmitted - is essential to assess optimal treatment regimens available to patients, and thereby prevent the further emergence and spread of resistant strains.

ACKNOWLEDGEMENTS

We would like to acknowledge all patients and their families. We especially thank Ms. Veronicah Kizza for her dedicated patient care and excellent work as our study nurse.

References

1. Kabugo C, Bahendeka S, Mwebaze R, et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: Evidence of extended virologic and CD4+ cell count responses. *J Acquir Immune Defic Syndr*. 2005;38(5):578-583.
2. Zuniga J. Out of Africa: Uganda and UNAIDS advance a bold experiment. *J Int Assoc Physicians AIDS Care*. 1999;5(10):48-60.
3. Gillespie S. *AIDS, Poverty, and Hunger*; 2006.
4. WHO. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection. Recommendations for a public health approach - Second edition;2016.
5. Uganda Population-based HIV Impact Assessment (UPHIA 2016-2017):
<http://www.afro.who.int/sites/default/files/2017-08/UPHIA%20Uganda%20factsheet.pdf>.
6. Lee GQ, Bangsberg DR, Muzoora C, et al. Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda. *AIDS Res Hum Retroviruses*. 2014;30(9):896-906. doi:10.1089/AID.2014.0043.

7. Nazziwa J, Njai HF, Ndembu N, et al. Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naïve individuals from Ugandan fishing communities of Lake Victoria. *AIDS Res Hum Retroviruses*. 2013;29(5):788-795. doi:10.1089/aid.2012.0123.
8. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2016;316(2):191-210. doi:10.1001/jama.2016.8900.
9. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naïve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. *Lancet*. 2012;380(9849):1250-1258. doi:10.1016/S0140-6736(12)61038-1.
10. Hamers RL, Sigaloff KCE, Kityo C, Mugenyi P, Wit TFR de. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. *Curr Opin HIV AIDS*. 2013;8(1):19-26. doi:10.1097/COH.0b013e32835b7f94.
11. Ssemwanga D, Lihana RW, Ugoji C, et al. Update on HIV-1 acquired and transmitted drug resistance in Africa. *AIDS Rev*. 2015;17(1):3-20.
12. Kaleebu P, Kirungi W, Watera C, et al. Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda. *PLoS ONE*. 2015;10(12):e0145536. doi:10.1371/journal.pone.0145536.
13. Nwaka S, Ochem A, Besson D, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. *BMC Int Health Hum Rights*. 2012;12:11. doi:10.1186/1472-698X-12-11.
14. Castelnovo B, Nsumba M, Musomba R, et al. Strengthening the "Viral Failure Pathway": Clinical Decision and Outcomes of Patients With Confirmed Viral Failure in a Large HIV

- Care Clinic in Uganda. *J Acquir Immune Defic Syndr*. 2015;70(5):e174-6.
doi:10.1097/QAI.0000000000000820.
15. WHO. HIV drug resistance report 2017.: Licence: CC BY-NC-SA 3.0 IGO;2017.
 16. Castelnovo B, Kiragga A, Afayo V, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. *PLoS ONE*. 2012;7(12):e51631. doi:10.1371/journal.pone.0051631.
 17. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic;2014.
 18. Reynolds SJ, Ssempijja V, Galiwango R, et al. Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda. *AIDS Res Hum Retroviruses*. 2017;33(5):448-451. doi:10.1089/AID.2015.0370.
 19. Yang W-L, Kouyos R, Scherrer AU, et al. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. *J Infect Dis*. 2015;212(1):28-38. doi:10.1093/infdis/jiv012.
 20. Castelnovo B, Kiragga A, Mubiru F, Kambugu A, Kanya M, Reynolds SJ. First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda. *J Int AIDS Soc*. 2016;19(1):20773.
 21. Nakiwogga-Muwanga A, Katabira E, Kiragga A, et al. Factors before enrolment are associated with being removed from a Pharmacy-only Refill Programme at a large urban HIV/AIDS clinic, Uganda. *Int J STD AIDS*. 2014;25(2):105-112.
doi:10.1177/0956462413492715.
 22. Assoumou L, Charpentier C, Recordon-Pinson P, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load 50 copies/mL: A 2014 French nationwide study. *J Antimicrob Chemother*. 2017;72(6):1769-1773. doi:10.1093/jac/dkx042.
 23. Hermans LE, Moorhouse M, Carmona S, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment

- programmes: A multicentre cohort study. *Lancet Infect Dis*. 2018;18(2):188-197.
doi:10.1016/S1473-3099(17)30681-3.
24. Reynolds SJ, Sendagire H, Newell K, et al. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. *BMC Infect Dis*. 2012;12:381. doi:10.1186/1471-2334-12-381.
25. Boender TS, Kityo CM, Boerma RS, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. *J Antimicrob Chemother*. 2016;71(10):2918-2927. doi:10.1093/jac/dkw218.
26. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: A systematic review and meta-analysis. *Lancet Infect Dis*. 2009;9(7):409-417. doi:10.1016/S1473-3099(09)70136-7.
27. Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. *Lancet Infect Dis*. 2010;10(3):155-166. doi:10.1016/S1473-3099(09)70328-7.
28. Hamers RL, Oyomopito R, Kityo C, et al. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. *Int J Epidemiol*. 2012;41(1):43-54. doi:10.1093/ije/dyq192.
29. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: A multicentre retrospective cohort study. *Lancet Infect Dis*. 2016;16(5):565-575. doi:10.1016/S1473-3099(15)00536-8.
30. Hassan AS, Nabwera HM, Mwaringa SM, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal

Kenya: A cross-sectional study. *AIDS Res Ther.* 2014;11(1):9. doi:10.1186/1742-6405-11-9.

31. Lessells RJ, Stott KE, Manasa J, et al. Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: Early experiences, achievements and challenges. *BMC Health Serv Res.* 2014;14:116. doi:10.1186/1472-6963-14-116.

TABLE & FIGURE LEGEND

Table 1: Baseline characteristics of patients with and without virological failure

Table 2: univariate and multivariate analyses of risk factors for virological failure in A) patients on first-line ART and B) patients on second-line ART

Figure 1: enrollment process

Figure 2: Type and frequency of most prevalent resistance-associated mutations observed among patients failing antiretroviral treatment

Figure 3: Type and frequency of most prevalent resistance-associated mutations observed among patients failing A) first-line and B) second-line antiretroviral treatment

Table 1: Baseline characteristics of patients with and without virological failure

Characteristics	Not failing N=2240	Failing first-line N=142	Failing second-line N=48
Female gender (N, %)	1395 (62.3)	102 (71.8)	29 (60.4)
Median age in years (IQR)	42 (35-49)	35 (28-42)	41 (35.8-45.5)
WHO disease stage (N, %)			
1, 2	806 (36.0)	60 (42.3)	11 (23.0)
3,4	1434 (64.0)	82 (57.7)	37 (77.0)
Median CD4 cell count in cells/ul (IQR)			
Current	491 (350-657)	254 (106.2-404.2)	325 (200-453)
Nadir	129 (44-235)	126.5 (43-202.8)	43.5 (9-106.5)
Median time on ART in years (IQR)	5.2 (2.8-9.4)	3.3 (1.8-5.1)	6.1 (4.3-9.9)
Current ART regimen (N, %)			
First-line NNRTI-based	1932 (86.3)	142 (100)	0
TDF + XTC + NVP	138	16 (11.3)	0
TDF + XTC + EFV	712	54 (38.0)	0
ZDV + XTC + NVP	624	47 (33.1)	0
ZDV + XTC + EFV	436	24 (16.9)	0
ZDV + 3TC + TDF	7	1 (0.7)	0
D4T + XTC + NVP	3	0	0
ABC + XTC + EFV	7	0	0
ABC + XTC + NVP	5	0	0
Second-line PI-based	308 (13.7)	0	48 (100)
ATV/r	86	0	16 (33.3)
LPV/r	222	0	32 (66.6)

Table legend: IQR= interquartile range; ART=antiretroviral therapy; NVP = nevirapine, EFV = efavirenz; TDF = tenofovir, ZDV = zidovudine, XTC = FTC or 3TC, ATV/r = ritonavir-boosted atazanavir, LPV/r = ritonavir-boosted lopinavir

Table 2: univariate and multivariate analyses of risk factors for virological failure in **A)** patients on first-line ART and **B)** patients on second-line ART

A. Patients on first-line ART

Variable	Univariate analysis			Multivariate analysis		
	OR	95% CI	p-value	OR	95% CI	p-value
age	0.12	(0.06,0.24)	<0.001	0.07	(0.02,0.22)	<0.001
Male gender	0.74	(0.54,1.03)	0.08	0.44	(0.27,0.71)	<0.001
CD4 cell count in cells/ul						
<200 (reference)						
200-350	0.07	(0.04,0.12)	<0.001	0.04	(0.02,0.09)	<0.001
351-500	0.12	(0.07,0.17)	<0.001	0.08	(0.04,0.14)	<0.001
501-650	0.23	(0.15,0.35)	<0.001	0.19	(0.11,0.32)	<0.001
>650	0.04	(0.02,0.08)	<0.001	0.02	(0.01,0.06)	<0.001
Previous viral load	0.62	(0.44,0.86)	0.005	0.64	(0.41,0.99)	0.05
Missed pills						
> 1/month (reference)						
Never	0.31	(0.2,0.48)	<0.001	0.33	(0.18,0.61)	<0.001
1/month	0.66	(0.39,1.1)	0.11	0.79	(0.4,1.55)	0.49
Side-effects	2.16	(1.43,3.25)	<0.001	2.01	(1.17,3.46)	0.01
Marital status						
Married (reference)						
single	2.19	(1.45,3.31)	<0.001	0.98	(0.54,1.78)	0.95
separated	1.95	(1.29,2.96)	0.002	2.21	(1.29,3.81)	0.004
widowed	1.01	(0.61,1.68)	0.98	1.36	(0.68,2.76)	0.39
cohabitating	1.35	(0.72,2.51)	0.35	1.43	(0.65,3.14)	0.38
Number of children						
0-3 (reference)						
>3	0.70	(0.5,0.96)	0.03	1.45	(0.89,2.35)	0.14

B. Patients on second-line ART

Variable	Univariate analysis			Multivariate analysis		
	OR	95% CI	p-value	OR	95% CI	p-value
age	0.12	0.06;2.97	0.39	0.43	0.06;2.97	0.39
Male gender	0.74	0.54;1.03	0.08	0.81	0.35;1.87	0.62
CD4 cell count in cells/ul						
<200 (reference)		(0.04,0.12)				
200-350	0.07	(0.07,0.17)	<0.001	0.27	(0.07,1.03)	0.06
351-500	0.11	(0.15,0.35)	<0.001	0.60	(0.19,1.86)	0.37
501-650	0.23	(0.02,0.08)	<0.001	0.70	(0.23,2.13)	0.53
>650	0.04		<0.001	0.10	(0.03,0.41)	0.001
Previous viral load	0.62	(0.44,0.86)	0.01	0.21	(0.09,0.52)	<0.001
Missed pills						
> 1/month (reference)						
Never	0.31	(0.2,0.48)	<0.001	1.11	(0.34,3.58)	0.87
1/month	0.66	(0.39,1.1)	0.11	1.28	(0.31,5.23)	0.73
Side-effects	2.18	(1.43,3.25)	<0.001	1.34	(0.39,4.55)	0.64
Marital status						
Married (reference)						
Single	2.19	(1.45,3.31)	<0.001	1.46	(0.55,3.92)	0.45
Separated	1.95	(1.29,2.96)	0.001	0.81	(0.27,2.47)	0.71
Widowed	1.01	(0.61,1.68)	0.98	0.64	(0.19,2.17)	0.47
cohabitating	1.35	(0.72,2.51)	0.35	0.80	(0.15,4.14)	0.80
Number of children						
0-3 (reference)						
>3	0.70	(0.5,0.96)	0.03	1.36	(0.59,3.11)	0.47

Table legend: ART = antiretroviral treatment, OR = odds ratio, CI = confidence interval

Figure 1: enrollment process

Figure legend: ART = antiretroviral treatment




Figure 2: Univariate and multivariate analysis of risk factors for virological failure

Figure legend: cART = combination antiretroviral therapy




Figure 3A: Type and frequency of most prevalent resistance-associated mutations observed among patients failing first-line antiretroviral treatment (N= 121)




Figure 3B: Type and frequency of most prevalent resistance-associated mutations observed among patients failing second-line antiretroviral treatment (N=36)




Figure legend: NRTI = Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNRTI = Non-Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; PI = Protease Inhibitors